We next compared the effects of calcitriol on the phenotype of activated CD4+ T cells isolated from the blood of a cohort of healthy donors (n = 15) or of patients with MS in the relapsing-remitting stage (RRMS, n = 11). This evidence concerns the gene CD4 and myeloid sarcoma.